Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OREX

Orexigen Therapeutics (OREX) Stock Price, News & Analysis

Orexigen Therapeutics logo

About Orexigen Therapeutics Stock (NASDAQ:OREX)

Advanced Chart

Key Stats

Today's Range
$0.22
$0.32
50-Day Range
$0.22
$0.22
52-Week Range
$0.17
$3.81
Volume
3.74 million shs
Average Volume
1.16 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products primarily in the United States, Europe, and South Korea. It offers Contrave for the treatment of obesity. The company also offers Contrave under the Mysimba brand name. Orexigen Therapeutics, Inc. was founded in 2002 and is headquartered in La Jolla, California. On March 12, 2018, Orexigen Therapeutics, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Receive OREX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orexigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

OREX Stock News Headlines

Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.
Xeno Biosciences Announces New CEO and Financing
Orexigen Tanks After-Hours on Obesity Data
See More Headlines

OREX Stock Analysis - Frequently Asked Questions

Orexigen Therapeutics, Inc. (NASDAQ:OREX) issued its quarterly earnings data on Monday, November, 13th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.13) by $0.78. Orexigen Therapeutics's revenue for the quarter was up 170.0% compared to the same quarter last year.

Based on aggregate information from My MarketBeat watchlists, some other companies that Orexigen Therapeutics investors own include Lexicon Pharmaceuticals (LXRX), Arena Pharmaceuticals (ARNA), MannKind (MNKD), Novavax (NVAX), Bristol-Myers Squibb (BMY), Rexahn Pharmaceuticals (REXN) and ImmunoGen (IMGN).

Company Calendar

Last Earnings
11/13/2017
Today
5/22/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:OREX
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

This page (NASDAQ:OREX) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners